EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study

Bob G Schultz, Michael Bullano, Deepika Paratane iD, Krithika Rajagopalan

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Bob G Schultz und 3 weiteren Autor:innen. Beteiligte Einrichtung: US Medical Affairs Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, Massachusetts, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Ribonucleosides, Organ Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceuticals U.S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) infections among hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) recipients impose a significant health care resource utilization (HCRU)‐related economic burden. Maribavir (MBV), a novel anti‐viral therapy (AVT), approved by the United States Food and Drug Administration for post‐transplant CMV infections refractory (with/without resistance) to conventional AVTs has demonstrated lower hospital length of stay (LOS) versus investigator‐assigned therapy (IAT; valgancilovir, ganciclovir, foscarnet, or cidofovir) in a phase 3 trial (SOLSTICE). This study estimated the HCRU costs of MBV versus IAT.

Methods

An economic model was developed to estimate HCRU costs for patients treated with MBV or IAT. Mean per‐patient‐per‐year (PPPY) HCRU costs were calculated using (i) annualized mean hospital LOS in SOLSTICE, and (ii) CMV‐related direct costs from published literature. Probabilistic sensitivity analysis with Monte‐Carlo simulations assessed model robustness.

Results

Of 352 randomized patients receiving MBV ( n = 235) or IAT ( n = 117) for 8 weeks in SOLSTICE, 40% had HSCT and 60% had SOT. Mean overall PPPY HCRU costs of overall hospital‐LOS were $67,205 (95% confidence interval [CI]: $33,767, $231,275) versus $145,501 (95% CI: $62,064, $589,505) for MBV and IAT groups, respectively. Mean PPPY ICU and non‐ICU stay costs were: $32,231 (95% CI: $5,248, $184,524) versus $45,307 (95% CI: $3,957, $481,740) for MBV and IAT groups, and $82,237 (95% CI: $40,397, $156,945) MBV versus $228,329 (95% CI: $94,442, $517,476) for MBV and IAT groups, respectively. MBV demonstrated cost savings in over 99.99% of simulations.

Conclusions

This analysis suggests that Mean PPPY HCRU costs were 29%–64% lower with MBV versus other‐AVTs. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsRibonucleosidesOrgan TransplantationHumansCytomegalovirusAntiviral AgentsGanciclovirHospitalizationTransplant RecipientsBenzimidazolesHematopoietic Stem CellsDichlororibofuranosylbenzimidazole

Stichwörter der Autor:innen

cost‐savingscytomegalovirus infectionhealthcare resource utilizationmaribavirorgan transplant recipients

Substanzen

Antiviral AgentsmaribavirGanciclovirBenzimidazolesRibonucleosidesDichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • US Medical Affairs Outcomes Research, Takeda Pharmaceuticals U.S.A., Inc., Lexington, Massachusetts, USA.
  • Health Economics and Outcomes Research, Anlitiks, Inc., Windermere, Florida, USA.

ORCID-Profile: Deepika Paratane

Förderung

  • Takeda Pharmaceuticals U.S.A.

Zitieren

APA

Schultz, B. G., Bullano, M., Paratane, D., & Rajagopalan, K. (2024). Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study. Transplant Infectious Disease. https://doi.org/10.1111/tid.14216

Vancouver

Schultz BG, Bullano M, Paratane D, Rajagopalan K. Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study. Transplant Infectious Disease. 2024. doi:10.1111/tid.14216

BibTeX
@article{Schultz2024,
  author = {Schultz, Bob G and Bullano, Michael and Paratane, Deepika and Rajagopalan, Krithika},
  title = {Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator‐assigned therapy: A US‐based study},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14216}
}
Kostenlos starten →